Evidence map›Paper›PMID 33199417›Full record

ArticleBMJ open2020

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7

Richard E Pratley, Vanita R Aroda, Andrei-Mircea Catarig, Ildiko Lingvay, Jörg Lüdemann, Emre Yildirim, Adie Viljoen

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02648204. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02648204 phase3completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Ran2016Enrolled1,201Registered outcomes28Posted comparisons6ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsDulaglutide, semaglutide
PMID 29764222PMID 30615985PMID 29246950PMID 30362224PMID 30865526PMID 29397376PMID 31168765PMID 30927241PMID 29557057other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  8. Observational
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Richard E PratleyTranslational Research Institute, AdventHealth, Orlando, Florida, USA Richard.Pratley.MD@AdventHealth.com.ORCID 0000-0002-2912-1389
Vanita R ArodaDivision of Endocrinology, Diabetes & Hypertension, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-7706-4585
Andrei-Mircea CatarigMedical and Science, Novo Nordisk A/S, Søborg, Denmark.
Ildiko LingvayDepartment of Internal Medicine/Endocrinology and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jörg LüdemannDiabetes-Falkensee, Diabetes Centre and Centre for Clinical Studies, Falkensee, Germany.
Emre YildirimGlobal Medical Affairs, Novo Nordisk A/S, Søborg, Denmark.
Adie ViljoenBorthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK.
Novo Nordisk (Denmark) · DKAdventHealth Orlando · USBrigham and Women's Hospital · USLister Hospital · GBThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn SUSTAIN 7, once-weekly semaglutide demonstrated superior glycated haemoglobin (HbA

designAnalyses by baseline age (<65, ≥65 years), sex (male, female), diabetes duration (≤5, >5-10, >10 years), HbA

setting194 sites; 16 countries.

participantsSubjects with T2D (n=1199) exposed to treatment.

interventionsSemaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly. PRIMARY AND SECONDARY OUTCOME MEASURES: Change in HbA

resultsHbA

conclusionsConsistently greater improvements in HbA TRIAL REGISTRATION NUMBER: NCT02648204.

Indexed as

Diabetes Mellitus, Type 2AgedFemaleGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsMaleRecombinant Fusion ProteinsSemaglutidedulaglutideGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsSemaglutideclinical trialsdiabetes & endocrinologygeneral diabetes

Identifiers

PMID33199417
PMCPMC7670946
OpenAlexW3102049033

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.